PROVEN TO PERFORM
Explore clinical data about the InterStimTM system and patient outcomes.
You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Explore clinical data about the InterStimTM system and patient outcomes.
Twenty years ago, Medtronic introduced sacral neuromodulation (SNM) and transformed how clinicians treat bladder and bowel control problems. Today, our therapies continue to demonstrate effective and lasting results in multiple studies.1,2
See evidence that demonstrates the efficacy of the InterStimTM system for reducing the symptoms of overactive bladder and non-obstructive urinary retention.1,3
SEE BLADDER SUMMARYView key data that prove the InterStimTM system can provide long-term relief of the symptoms of chronic fecal incontinence.2
SEE BOWEL SUMMARYTake convenient courses specifically designed for clinicians treating patients with OAB, non-obstructive urinary retention, and chronic fecal incontinence.
SEE COURSESSiegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. The Journal of Urology 2018;Volume 199(1), 229–236.
Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.
Medtronic InterStimTM Therapy Clinical Data Summary (2018).